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Overall, we identified 205 patients according to inclusion
criteria—an annual incidence of 43.8/106 (95% confidence
interval (CI) 38.1 to 50.3) (table 1). The most common type of
vasculitis was HSV/LCV with an annual incidence of 26.0/106
(95% CI 21.7 to 31.2). The incidence of PAN was found to be
7.7/106 (95% CI 5.5 to 10.7), HSP 3.0/106 (95% CI 1.7 to 5.1),
TA 2.3/106 (95% CI 1.2 to 4.3), WG 2.1/106 (95% CI 1.1 to 4.1),
TAA 1.3/106 (95% CI 0.5 to 2.9), and CSS 1.3/106 (95% CI 0.5
to 2.9) annually. Six patients in the PAN group and eight in
the HCV/LCV group responded to the definition of MPA being
antineutrophil cytoplasmic antibody (ANCA) positive and/or
having nephritis in addition to other system involvement.
Therefore, the annual incidence of presumed MPA was 3.0/
106 (95% CI 2.0 to 5.7) in total. The diagnoses of 66/205
patients were supported by biopsy data. Five of 36 patients
with PAN, 8/10 patients with WG, and 4/5 with CSS were
found to be ANCA positive.
Three studies, Kristiansand (Norway),5 Norwich (Norfolk,
England)3 4 6, and Lugo (Spain)7 were selected for comparison
with our study (table 1). The annual incidence of PSV in
Vilnius seems to fall in between the figures of annual
incidence reported in Norwich (38.6/106, TA excluded),
Kristiansand (54.5/106), and Lugo (115.0/106). However, the
distribution of the annual incidence of distinct vasculitides
differs from those of other European studies. The most
important difference was noted for TA and less notably for
WG (table 1). The annual incidence of MPA was in
accordance with the lower figures reported in the European
studies and less than half that quoted in the study by Watts
et al.3
The shorter life expectancy of Lithuanian people, which in
1999 was 71 years and lower than that of the European
population, might be a potential explanatory factor for the
lower incidence of TA in Vilnius. Possibly, because a
histological examination was rarely carried out, and the
ANCA test was introduced only after 1995,8 WG and other
ANCA associated vasculitides cases are underrepresented,
especially in the first 5 years of this study.
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O
steoporosis is a well known feature of rheumatoid
arthritis (RA).1 Cross sectional studies have shown
that patients with RA have a lower bone mineral
density (BMD) than healthy controls.2 Disease activity,
steroid use, and immobility are associated with loss of
BMD in RA.3–7 It has been suggested that active treatment of
patients with RA may prevent loss of BMD.8 The current most
effective drugs in the treatment of RA are the tumour
necrosis factor a blocking agents. The beneficial effects of
short term treatment with infliximab on markers of bone
metabolism in patients with active RA have recently been
shown.9 From this we proposed the hypothesis that bone loss
might be arrested in patients with RA during treatment with
infliximab.
METHODS AND RESULTS
This open cohort study consisted of consecutive patients
with RA, who were treated with infliximab in the Slotervaart
Hospital and the VU University Medical Centre. All
patients fulfilled the ACR 1987 criteria of RA and had
active disease (defined by the modified 28 joint count
Disease Activity Score (DAS28) of at least 3.2). Infliximab
was given intravenously at 0, 2, 6, 14, weeks and from
the fourth infusion every 8 weeks in a dose of 3 mg/kg.
At each visit the DAS28 was calculated and changes
in drug treatment were recorded. BMD measurements
(g/cm2) of the hip (total hip) and lumbar spine (L1–4)
were performed at baseline and after 1 year on a Hologic
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In total, 36 patients (29 (81%) female) were included into
the study. Patients had a mean (SD) age of 53 (12) years,
with a median (range) disease duration of 9.5 years (0–49).
Methotrexate, prednisone, and bisphophonates were used by
100%, 50%, and 25% of the patients, respectively. The mean
disease activity (DAS28) decreased from 5.6 at baseline to 3.8
at 6 weeks and stabilised around 3.6 for the rest of the
studied period. In 36 patients dual x ray absorptiometry
(DXA) measurements of lumbar spine (L1–4) and in 30
patients DXA measurements of the hip were available at
baseline and after 1 year. In four patients no DXA hip
measurements were available because of bilateral hip
replacement, and in two patients only one DXA of the hip
was available owing to unknown causes.
Mean (SD) BMD at the lumbar spine increased non-
significantly from 0.998 (0.205) to 1.001 (0.199) at 1 year
(+1.1%, p = 0.117). BMD at the total hip decreased non-
significantly from 0.857 (0.144) to 0.854 (0.132) at 1 year.
(20.3%, p = 0.683). In a linear regression model, changes in
BMD at the hip or the spine were not associated with mean
DAS28, prednisone use, or bisphosphonate use (data not
shown).
DISCUSSION
This study indicates that BMD of the spine has a tendency to
increase and that BMD of the hip slightly decreases during
1 year of treatment with infliximab. This is in contrast with
previous longitudinal studies of patients with RA, in which a
decrease of BMD was seen during conventional disease
modifying antirheumatic drug treatment without tumour
necrosis factor blockings agents (table 1).
In our view, these data suggest that treatment with
infliximab can arrest generalised osteoporosis in patients
with RA. This view is supported by the observation that
markers of bone formation increased and markers of bone
resorption decreased in the first 6 weeks of treatment with
infliximab.7 We do realise that our observations are made in
an open cohort study and therefore no definite conclusions
can be drawn from our data.
In summary, this study suggests that treatment with
infliximab has a positive effect on BMD in patients with RA.
Because patients with RA have an increased risk of bone loss
and, subsequently, osteoporotic fractures, this might be an
additional advantage of infliximab (above the well known
favourable effect on disease activity and radiological
damage), and warrants further study.
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Table 1 Summary of changes in BMD of five studies in patients with RA
Study
Patients
RA
Follow up
BMD change (%)
(n) (years) Hip Spine
Boers10` 62 Early 1 21.3 20.3
Gough5 50 Early 1 24.2 22.4
Haugeberg3 366 Established 2 20.77 20.29
Dolan8 21 Established 2 0.0* 21.02*
Shibuya2 146 Established 1 No data 21.1*
This study 36 Established 1 20.3 +1.1
* Percentage change calculated from data given in the manuscript; BMD of the spine was not measured; `data
from the patients treated with sulfasalazine alone.
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